ArticleFrontiers in oncology2022
30-Year Experience With 22 Cases of Malignant Transformation Arising From Ovarian Mature Cystic Teratoma: A Rare Disease.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Malignant transformation of mature ovarian teratoma into goblet cell adenocarcinoma: a case report.Gynecologic oncology reports · 2026Article
- Management of Dermoid Cysts During Pregnancy: A Retrospective Analysis From a Tertiary Care Center.Cureus · 2026Article
- Frequency and clinicopathological features of somatic neoplasms arising in ovarian mature teratomas: a single-center experience.Pathology oncology research : POR · 2026Article
- Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study).Archives of gynecology and obstetrics · 2025Article
- Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma.Human cell · 2025Article
- Size threshold as a risk for malignant transformation in typical ovarian dermoid lesions: a scoping review.Abdominal radiology (New York) · 2025Article
- Immunotherapy in young adults with mature cystic ovarian Teratoma-Derived squamous cell carcinoma: a case series.Journal of ovarian research · 2025Article
- Single-Nucleus RNA Sequencing and Spatial Transcriptomics for Squamous Cell Carcinoma Arising From Ovarian Mature Teratoma.Cancer science · 2025Article
- A Challenging Diagnosis of Papillary Thyroid Carcinoma Arising From Malignant Struma Ovarii.Cureus · 2025Article
- Article
- The prognostic significance of primary tumor laterality in malignant ovarian teratomas: a 10-year experience at a single institution.Frontiers in immunology · 2025Article
- Papillary Thyroid Carcinoma Arising Within a Mature Ovarian Cystic Teratoma: A Case Report.Case reports in endocrinology · 2025Article
- MRI features of ovarian teratomas with somatic-type malignancy and mature cystic teratomas.Abdominal radiology (New York) · 2024Article
- MRI findings of malignant transformation arising from mature cystic teratoma of the ovary: comparison with benign mature cystic teratoma.Japanese journal of radiology · 2024Article
- Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A case report.SAGE open medical case reports · 2024Article
- A rare case of squamous cell carcinoma transformation in a mature cystic teratoma of the ovary.SAGE open medical case reports · 2023Article
- High-Grade Endometrioid Stromal Sarcoma of the Ovary: Malignant Transformation of Ovarian Mature Cystic Teratoma.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical characteristics and survival outcomes of patients with malignant transformation arising from ovarian mature cystic teratoma (MT-MCT). Methods: This retrospective study included patients with ovarian MCTs at Peking Union Medical College Hospital (PUMCH) during 1990.01-2020.12. When the pathologic histology was MT-MCT, detailed information was collected. Results: Overall, 7229 ovarian MCT patients and 22 patients with MT-MCT were enrolled. The rate of malignant transformation of all ovarian MCTs was 0.30%. Most patients with MT-MCT were 51 (21-75) years old, and the tumor mass size was 10 (3-30) cm. The typical clinical symptoms were mainly abdominal pain and distension. The levels of tumor markers were elevated on preoperative examination. Early diagnosis could be made by ultrasonic examination, pelvic enhanced MRI and CT. Most patients underwent debulking surgery and adjuvant chemotherapy. The most common histological type to exhibit malignant transformation was squamous cell carcinoma (59.1%), followed by adenocarcinoma (13.6%), carcinoid (9.1%), and borderline tumor (18.2%). The 5-year RFS and OS rates were 54.5% and 81.8%, respectively. Patients with FIGO stage I had the best RFS (P=0.047) and OS (P=0.018), followed by those with FIGO stage II-IV. Conclusion: MT-MCTs mainly occur in elderly females, are rare and have a poor prognosis. Advanced FIGO stage is a risk factor for survival. Although there is no standard treatment, cytoreductive debulking surgery and adjuvant chemotherapy could be considered. Perimenopausal and menopausal women with MCT should receive surgical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.